RED DESERT: Results from first five patients indicaterepeated dose alfapump DSR therapy to be safeandeffective Interim data support DSR hypothesis: kidneys eliminate free water to maintain patients’ serum sodium levels No patients required loop diuretic therapy during the six-week alfapump DSR treatment period Followingalfapump DSR treatment, loop diuretic responsiveness was restored to near normal levels; effect was durable for months post-treatmentwith majority of patients requiring little or no diuretic therapy Full RED DESERT data on track […]
Coronary/Structural Heart
FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)
In non-dialysis and dialysis-dependent CKD patients, Major Adverse Cardiovascular Event (MACE) and MACE+ incidence rates were lowest when patients achieved hemoglobin levels ≥ 10 g/dL Two analyses of pooled data from the roxadustat global Phase 3 development program to be presented during the American Society of Nephrology Kidney Week 2020 Reimagined SAN FRANCISCO, Oct. 22, 2020 […]
Hatch Medical and VascuTech Medical Partner to Commercialize Advanced Radial Sheath and Micro-Introducer Lines
SANTA ROSA BEACH, Fla., Oct. 20, 2020 (GLOBE NEWSWIRE) — Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C. (www.hatchmedical.com) announced recently that it has entered into an exclusive brokerage relationship with VascuTech Medical and Interventional Radiologist Jonathan Levine, MD for their next generation sheath technology. “Dr. Levine, a […]
CARMAT Obtains ANSM Approval to Resume PIVOTAL Study Implants in France
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that it has obtained ANSM (French agency for the safety of […]
PleuraFlow Shown to Enable Improved Outcomes for Cardiac Surgery Patients in New Clinical Study Results
Reduction of Patient Complications After Heart Surgery Demonstrated with Use of the ClearFlow’s PleuraFlow ACT System IRVINE, Calif.–(BUSINESS WIRE)–ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results presented at the 2020 Virtual Program of the Annual Eastern Cardiothoracic Surgical Society Conference (ECTSS) on […]
Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure
MIAMI, Oct. 20, 2020 (GLOBE NEWSWIRE) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“RCN”). Organicell and RCN plan to collaborate on clinical research projects investigating use […]
OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System’s Bioresorbable Coated Drug-Eluting Coronary Stent
OPTIMIZE Pivotal Study 1 Year Outcomes Announced at TCT Connect NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–The Svelte® Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study. Primary and secondary endpoint outcomes of the OPTIMIZE IDE study, designed […]
Cardiac Dimensions Announces up to 7.5 Year Data on the Carillon® Mitral Contour System
Have you seen the exciting new publication by Dr. Janusz Lipiecki and team, Long-term prognosis of patients treated by coronary sinus-based percutaneous annuloplasty: single centre experience, published in ESC Heart Failure 2020? This publication is Cardiac Dimension’s sixth this year! The company continues to release data which confirms the Carillon Mitral Contour System’s importance in the treatment of heart […]
CeloNova Announces Late-Breaking Evidence From First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT In Complex Patients At High Bleeding Risk Following PCI
The novel non-DES, non-BMS COBRA PzF NanoCoated Coronary Stent (NCS) with just 14-days DAPT demonstrated statistically less bleeding (BARC 1-5) compared to the DES arm at 3 or 6 months DAPT post-PCI, low 0.6% ST and low 3.7% ischemic-driven TLR at 6 months. SAN ANTONIO, Oct. 17, 2020 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), […]
Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women
DANVERS, Mass.–(BUSINESS WIRE)–Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI. The findings were presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. In the first study, presented by Hemindermeet Singh, […]



